The role of MS-377, a novel selective σ " ligand currently being developed for the treatment of schizophrenia, in modulating the activities of phencyclidine (PCP) on NMDA-induced calcium increase was examined in primary cultured neocortical neurons using calcium-imaging technique combined with a confocal laser scanning microscope. PCP significantly blocked NMDA-induced increases in intracellular calcium. The blockade by PCP of NMDA response was attenuated by both MS-377 and another highly selective σ " ligand, 3-PPP. The results agree with the interpretation that σ ligands may directly or indirectly modulate NMDA receptor complex functions, and may suggest that MS-377 might be therapeutically useful in cases of PCP-induced psychosis or schizophrenia.
Introduction
The initial interest in sigma (σ) receptors that have a functional similarity to phencyclidine (PCP)-binding sites on the NMDA calcium channel was due to both their antipsychotic (Largent et al., 1986 ) and psychotomimetic activities (Martin et al., 1976) . Recent observations suggested that the PCP and\or σ sites may be important for the production of schizophrenic symptoms, and that the antipsychotic effects of σ ligands may directly (Whittemore et al., 1997) or indirectly (Hayashi et al., 1995) modulate NMDA receptor complex function through σ receptors.
In the present experiment, we examined whether or not (R)-(j)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl) piperazin -1 -yl]methyl -2 -pyrrolidinone - -tartrate (MS-377), a novel selective σ " ligand currently being developed for the treatment of schizophrenia (Takahashi et al., 1999) , contributes to the activities of PCP on NMDAinduced calcium signals in primary cultures of rat neocortical neurons. The effects of a putative σ " receptor ligand, 3-PPP, were also compared with those of MS-377. A calcium-imaging technique combined with a confocal laser scanning microscope (CLSM) was employed in the study.
Materials and methods

Cell culture
Primary neocortical cell cultures were prepared from 17-to 19-d-old Wistar rat embryos ( Japan SLC Inc., Shizuoka, Japan). Great effort was taken to ensure that animal suffering was minimized, and to reduce the number of animals used. Neocortices of rats were dissected and placed in ice-cold Ca# + -and Mg# + -free PBS medium. The tissue was then cut into fine fragments which were treated with 10 ml 0n25 % trypsin (Gibco-BRL, USA)\0n01 % DNase I (Sigma Chemical Co., USA). After 14 min of incubation at 32 mC, the tissue was dissociated and 10 ml cold horse serum was added to cell suspension to stop trypsin activity. The cell suspension was then centrifuged and suspended in DMEM (Gibco-BRL, USA) containing 10 % horse serum, 10 % foetal calf serum, and 1 % penicillin\streptomycin. After two washes with fresh medium and centrifugation, the cells (3-5i10& cells\ml) were plated onto Polyethylenimine (Sigma, USA) pretreated coverslips in 35-mm cell culture dishes. Cultures were maintained at 37 mC in a humidified incubator containing 5 % CO # \95 % room air, and were fed by replacing half the medium on the following day and then twice a week. In the present study, all neurons were used after 10 d in culture, at which time the agonist effects were maximal.
Solutions and compounds
Calcium imaging was performed in an extracellular solution consisting of 126 m NaCl, 4 m KCl, 2 m CaCl # , 10 m Hepes, and 15 m glucose. The osmolarity was set at 320 mosmol\l, and pH was adjusted to 7n4. For extracellular drug application, all compounds were dissolved in this solution. Tetrodotoxin (1 µ ; Sigma, USA) was included in this solution for all experiments. In Ca# + -free experiments, CaCl # was omitted and 10 m EGTA was added. The following compounds were used :
Calcium measurement
The Oregon Green AM-loaded neurons were visualized using a real-time CLSM (Odyssey, Noran Instruments, USA) with a Nikon WI objective lens (i40, NA 1n15). Extracellular application of agents was performed through a DAD-12 Superfusion System (ALA Scientific Instruments, NY, USA). Two successive applications, i.e. NMDA alone (the first application) and NMDAjdrugs (the second application), to the same group of cells were performed in the present study. Image data acquisition was started 2 s before drug application. An increase in intracellular calcium ([Ca# + ] i ) concentration was induced by extracellular application of NMDA at a 1-s application duration. All drugs were applied 30 s before and during their corresponding NMDA application. In the experiments investigating the interactions between σ ligands and PCP, the σ ligands were applied 10 s before and during PCP application. Experiments were always performed with at least a 5-min wash time before the second agonist was applied.
For off-line ratio imaging analysis, the following calculation formulae were used :
where F pre and F peak represent the fluorescence intensities measured at the baseline and the peak response of stimulation, respectively. F bg-pre and F bg-peak are the fluorescence intensities measured in a background area without cells at the times of pre-and peak-stimulation, respectively. The net effect of stimulation was expressed as the ratio ∆F\F ! .
Results
While MS-377 in itself showed no effects on [Ca# + ] i (Figure 1a) , it blocked NMDA-induced calcium increases in a dose-dependent manner. The dose-response curve for the MS-377 block of NMDA-induced [Ca# + ] i is shown in Figure 1b . As described in the Materials and methods section, the DAD-12 Superfusion System enables the generation of reproducible increases in fluorescence upon multiple applications of agonist. We observed no difference in fluorescence changes between the first and second applications of NMDA (100 µ) [ Figure 1c ; F(1,109) Figure 1c ; F(1,63) l 58n11, p 0n01, n l 32, ANOVA]. Under our experimental system and conditions, both MS-377 (1 µ) and 3-PPP (10 µ) attenuated NMDA-induced fluorescence changes to 37n2 % and 57n3 % of controls, respectively [ Figure 1c ; F(1,59) l 90n56, p 0n01, n l 30 ; F(1,67) l 35n58, p 0n01, n l 34 for MS-377 and 3-PPP, respectively]. However, it is of great interest that even at concentrations that blocked NMDA responses when the ligands were applied alone, both of the σ ligands reversed PCP-induced blockade of NMDA responses. Compared to PCP application alone (28n5 %), additional applications of both MS-377 and 3-PPP attenuated the blockade by PCP of NMDA-induced increases in [Ca# + ] i to 75n4 and 69n5 % of controls, respectively [F(1,58) l 47n65, p 0n01, n l 27 ; F(1,70) l 82n45, p 0n01, n l 39 for MS-377 and 3-PPP, respectively].
Discussion
The exact mechanism(s) by which σ ligands act to mediate their pharmacological effects either in vitro or in vivo remains equivocal. At the concentrations used in the present study, both MS-377 and 3-PPP attenuated NMDA-induced calcium increase. This is in accordance with previously reported calcium attenuating effects of σ ligands on NMDA-induced calcium signalling in primary rat neuronal cultures (Hayashi et al., 1995) . However, others have reported that σ ligands, including 3-PPP and MS-377 attenuates blockade by PCP of NMDA response (Monnet et al., 1992) or in vitro (Malouf et al., 1988) experiments. The reason for the discrepancy between the above-cited observations is not clear, but may relate to several methodological differences, distinct reagents and concentrations used, differences in the experimental protocol, and subsequent quantitative data analysis methods.
Drugs such as PCP that interact with PCP-and σ-binding sites can produce psychotomimetic effects that resemble some symptoms of schizophrenia. Pharmacological profiles of PCP have been studied intensively with respect to its blockade of the NMDA ion-channel receptors (Fagg, 1987) . In-vivo study in animals demonstrated that PCP-induced abnormal behaviours were significantly attenuated by σ " ligands (Okuyama et al., 1994) . In addition, Weissman et al. (1991) provided the first evidence for alterations in σ-binding sites in schizophrenia. Taken together, all these results suggest that PCP and σ receptors may play putative role in PCP-induced psychosis as well as in the clinical manifestations of schizophrenia, and that selective σ ligands may be useful in the treatment of these disorders.
Although neither the physiological function of σ receptors nor the pharmacological effects of σ ligands are known, the calcium attenuating effects of σ ligands on NMDA-stimulated rat neocortical neurons in the present study suggest that the σ receptors may be capable of modulating the function of NMDA receptors. In fact, direct (Whittemore et al., 1997) or indirect (Hayashi et al., 1995) modulation by σ ligands (presumably through σ " sites) on the NMDA receptor ion-channel complex were previously reported. It is of great interest that in the present study both MS-377 and 3-PPP, even at concentrations that blocked NMDA responses by themselves, reversed PCP-induced blockade of NMDA responses. Consistent with our in-vitro study, an animal behavioural study (Takahashi et al., 1999) affinity only for σ " receptors (Takahashi et al., 1999 ) other than at the σ # , PCP, dopamine, and serotonin sites, the antipsychotic activities are likely to be associated at least in part with σ " receptors. In summary, although further experiments are necessary to elucidate the mechanisms of the calcium attenuating effects and anti-PCP effects of σ ligands on NMDA receptors, using calcium-imaging technique combined with a CLSM we demonstrated that both highly selective σ " ligand, MS-377, attenuated the blockade by PCP of NMDA-induced calcium increase in primary cultured neocortical neurons. These anti-PCP effects of MS-377 in vitro are consistent with previously reported animal behavioural studies in vivo, and if those findings can be extrapolated to humans, they may suggest that σ " receptor ligands, such as MS-377, might be therapeutically useful in cases of PCP-induced psychosis or schizophrenia.
